Action SAGE SAGE THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Sage Therapeutics, Inc.

Actions

SAGE

US78667J1088

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
13,69 USD +0,81% Graphique intraday de Sage Therapeutics, Inc. +2,70% -36,83%
26/04 SAGE THERAPEUTICS, INC. : Truist Securities est neutre ZM
25/04 Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease
Top Midday Decliners
Sector Update: Health Care Stocks Advance Premarket Wednesday
Sector Update: Health Care
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday
Top Premarket Decliners
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board
Sage Therapeutics to Present at Upcoming March Investor Conferences
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SAGE
  4. Actualités Sage Therapeutics, Inc.
  5. Autres langues